Irene Chong
Senior Researcher
Division of Molecular Pathology
The Institute Of Cancer Research
United Kingdom
Biography
Dr Irene Chong undertook her PhD in cancer biology under the supervision of Professor Alan Ashworth, and is now an NIHR Biomedical Research Centre Clinician Scientist at The Institute of Cancer Research and a Consultant Clinical Oncologist at The Royal Marsden. Dr Chong aims to discover new therapeutic targets and biomarkers for oesophageal and rectal cancers through DNA sequencing of cancer cells.
Research Interest
Dr Chong works in the ICR’s Division of Molecular Pathology and The Royal Marsden’s Gastrointestinal Clinical Trials Unit where she develops biomarker-driven, proof-of-concept clinical trial protocols based on discoveries made in the laboratory. She collaborates closely with The Royal Marsden’s Rectal Cancer Study Group and the Pelican Cancer Foundation to identify radiological and molecular predictors of response to chemotherapy and radiotherapy for patients with rectal cancer, and to establish new therapeutic targets that could be exploited in combination with radiotherapy to improve treatment. She received several awards during her PhD, including the University of London Scholarship Award, the Fourth NIHR Infrastructure Experimental Medicine Research Award, and the Royal College of Radiologists Kay Visiting Award, which enabled her to undertake a fellowship at the MD Anderson Cancer Centre.
Publications
-
Optimal treatment of metastatic pancreatic cancer. Cunningham D, Chong I.
-
Large-Scale Profiling of Kinase Dependencies in Cancer Cell Lines. Campbell J, Ryan CJ, Brough R, Bajrami I, Pemberton HN, Chong IY, Costa-Cabral S, Frankum J, Gulati A, Holme H, Miller R, Postel-Vinay S, Rafiq R, Wei W, Williamson CT, Quigley DA, Tym J, Al-Lazikani B, Fenton T, Natrajan R, Strauss SJ, Ashworth A, Lord CJ.
-
Gene and pathway level analyses of germline DNA-repair gene variants and prostate cancer susceptibility using the iCOGS-genotyping array. Saunders EJ, Dadaev T, Leongamornlert DA, Al Olama AA, Benlloch S, Giles GG, Wiklund F, Gronberg H, Haiman CA, Schleutker J, Nordestgaard BG, Travis RC, Neal D, Pasayan N, Khaw KT, Stanford JL, Blot WJ, Thibodeau SN, Maier C, Kibel AS, Cybulski C, Cannon-Albright L, Brenner H, Park JY, Kaneva R, Batra J, Teixeira MR, Pandha H, Govindasami K, Muir K; UK Genetic Prostate Cancer Study Collaborators; UK ProtecT Study Collaborators; PRACTICAL Consortium, Easton DF, Eeles RA, Kote-Jarai Z.
-
Gefitinib and EGFR Gene Copy Number Aberrations in Esophageal Cancer. Petty RD, Dahle-Smith A, Stevenson DAJ, Osborne A, Massie D, Clark C, Murray GI, Dutton SJ, Roberts C, Chong IY, Mansoor W, Thompson J, Harrison M, Chatterjee A, Falk SJ, Elyan S, Garcia-Alonso A, Fyfe DW, Wadsley J, Chau I, Ferry DR, Miedzybrodzka Z.
-
Mapping genetic vulnerabilities reveals BTK as a novel therapeutic target in oesophageal cancer. Chong IY, Aronson L, Bryant H, Gulati A, Campbell J, Elliott R, Pettitt S, Wilkerson P, Lambros MB, Reis-Filho JS, Ramessur A, Davidson M, Chau I, Cunningham D, Ashworth A, Lord CJ.
